Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s (Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), FRA:SCP) Chief executive, Professor Lindy Durrant joins Proactive London to talk about the progression made during the last year.
Following a £48 million raise during the period, the company is now well-funded and expects to deliver progress on its candidate pipeline over the next year and a half which Lindy talks through in detail, pursuing several clinical programmes across its vaccine and antibody portfolios.
Some of the programmes include Modi-1, with first patients for a Phase 1/2 study on solid tumours to start shortly with safety and tolerability data expected in 2022. And Modi-2, the second therapeutic vaccine candidate from the Moditope platform, anticipated to start GMP manufacturing during 2022.
And a phase 1 study for the Coronavirus (COVID-19) vaccine candidate started this month with safety data anticipated to be available in the first half of 2022.